A Study Evaluating Desvenlafaxine Sustained Release (DVS SR) in Adult Female Outpatients With Fibromyalgia
NCT ID: NCT00696787
Last Updated: 2013-02-25
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
125 participants
INTERVENTIONAL
2008-06-30
2009-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Evaluating the Efficacy of DVS-233 in Fibromyalgia
NCT00301431
The Efficacy and Safety of Pregabalin Combined With Desvenlafaxine in Patients With Fibromyalgia
NCT07171320
GW679769 In Fibromyalgia
NCT00264628
The Efficacy and Safety of Pregabalin Combined With Toludesvenlafaxine in Patients With Fibromyalgia
NCT07208357
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
NCT01432236
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
In the first stage, subjects were randomly assigned to receive placebo. Study was stopped after stage 1 by sponsor.
Placebo
DVS SR
In the first stage, subjects were randomly assigned to receive DVS SR 200 mg/day. Study was stopped after stage 1 by sponsor.
Desvenlafaxine Sustained Release (DVS SR)
Pregabalin
In the first stage, subjects were randomly assigned to receive Pregabalin 450 mg/day. Study was stopped after stage 1 by sponsor.
Lyrica® (Pregabalin)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Desvenlafaxine Sustained Release (DVS SR)
Lyrica® (Pregabalin)
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Other painful conditions that may confound the diagnosis or assessment of fibromyalgia
* Treatment with other drugs for fibromyalgia with 14 days of study start or during the study
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wyeth is now a wholly owned subsidiary of Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor
Role: STUDY_DIRECTOR
Wyeth is now a wholly owned subsidiary of Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Huntsville, Alabama, United States
Roseville, California, United States
San Diego, California, United States
San Diego, California, United States
Santa Ana, California, United States
Walnut Creek, California, United States
Jacksonville, Florida, United States
Tampa, Florida, United States
Decatur, Georgia, United States
Evansville, Indiana, United States
Indianapolis, Indiana, United States
Lexington, Kentucky, United States
Rockville, Maryland, United States
Lansing, Michigan, United States
Raleigh, North Carolina, United States
Cincinnati, Ohio, United States
Dayton, Ohio, United States
Duncansville, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Chattanooga, Tennessee, United States
Chattanooga, Tennessee, United States
Knoxville, Tennessee, United States
Austin, Texas, United States
Dallas, Texas, United States
San Antonio, Texas, United States
Salt Lake City, Utah, United States
Middleton, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
3151A4-2003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.